David J. Joyner
CIK 1515598 · View on SEC EDGAR ↗
First SEC filing: April 2, 2026 · Latest: April 2, 2026
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Aug. 6, 2014 | CVS | S 10b5-1 | 45,897 | $76.10 | $3,492,762 | 45,399 Direct | -50.27% | Disposed | 25.7% (price as of 2026-08-19) |
| Aug. 6, 2014 | CVS | S 10b5-1 | 77,619 | $76.10 | $5,906,806 | 45,399 Direct | -63.10% | Disposed | 25.7% (price as of 2026-08-19) |
| Jan. 3, 2014 | CVS | S 10b5-1 | 95,135 | $70.47 | $6,704,163 | 28,540 Direct | -76.92% | Disposed | 35.7% (price as of 2026-08-19) |
| Jan. 3, 2014 | CVS | S 10b5-1 | 125,250 | $70.50 | $8,830,125 | 28,540 Direct | -81.44% | Disposed | 35.6% (price as of 2026-08-19) |
| Sept. 19, 2012 | CVS | S 10b5-1 | 33,903 | $48.00 | $1,627,344 | 21,786 Direct | -60.88% | Disposed | 99.2% (price as of 2026-08-19) |
| Sept. 13, 2012 | CVS | S 10b5-1 | 20,000 | $47.00 | $940,000 | 1,786 Direct | -91.80% | Disposed | 103.5% (price as of 2026-08-19) |
| July 19, 2012 | CVS | S 10b5-1 | 10,000 | $47.00 | $470,000 | 21,786 Direct | -31.46% | Disposed | 103.5% (price as of 2026-08-19) |
| July 19, 2012 | CVS | S 10b5-1 | 30,000 | $46.20 | $1,386,000 | 31,786 Direct | -48.55% | Disposed | 107.0% (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| April 1, 2025 | CVS | Stock Option [F2] | Common Stock (226,138) | $67.98 | April 1, 2035 | 226,138 | Acquired |
| Nov. 30, 2024 | CVS | Premium Stock Appreciation Right [F1] | Common Stock (492,537) | $71.82 | Nov. 30, 2031 | 492,537 | Acquired |
| Nov. 30, 2024 | CVS | Premium Stock Option [F1] | Common Stock (1,000,000) | $71.82 | Nov. 30, 2031 | 1,000,000 | Acquired |
| Nov. 30, 2024 | CVS | Premium Stock Option [F2] | Common Stock (1,492,537) | $71.82 | Nov. 30, 2031 | 1,492,537 | Acquired |
| April 1, 2023 | CVS | Stock Option [F1] | Common Stock (51,959) | $74.31 | April 1, 2033 | 51,959 | Acquired |
| April 3, 2017 | CVS | Stock Option | Common Stock (35,062) | $78.05 | April 3, 2024 | 35,062 | Acquired |
| April 1, 2016 | CVS | Stock Option | Common Stock (25,093) | $104.82 | April 1, 2023 | 25,093 | Acquired |
| April 1, 2015 | CVS | Stock Option | Common Stock (23,968) | $102.26 | April 1, 2022 | 23,968 | Acquired |
| Aug. 6, 2014 | CVS | Stock Option | Common Stock (45,897) | $36.23 | April 1, 2017 | 45,897 | Disposed |
| Aug. 6, 2014 | CVS | Stock Option | Common Stock (77,619) | $28.10 | April 1, 2016 | 77,619 | Disposed |
| April 1, 2014 | CVS | Stock Option | Common Stock (25,177) | $74.29 | April 1, 2021 | 25,177 | Acquired |
| Jan. 3, 2014 | CVS | Stock Option | Common Stock (95,135) | $41.17 | April 1, 2015 | 95,135 | Disposed |
| Jan. 3, 2014 | CVS | Stock Option | Common Stock (125,250) | $34.42 | April 2, 2014 | 125,250 | Disposed |
| April 1, 2013 | CVS | Stock Option | Common Stock (23,604) | $54.53 | April 1, 2020 | 23,604 | Acquired |
| Sept. 19, 2012 | CVS | Stock Option | Common Stock (33,903) | $20.23 | March 1, 2015 | 33,903 | Disposed |
| Sept. 13, 2012 | CVS | Stock Option | Common Stock (20,000) | $20.23 | March 1, 2015 | 20,000 | Acquired |
| July 19, 2012 | CVS | Stock Option | Common Stock (40,000) | $20.23 | March 1, 2015 | 40,000 | Disposed |
| April 2, 2012 | CVS | Stock Option | Common Stock (35,492) | $45.07 | April 2, 2019 | 35,492 | Acquired |
| April 1, 2011 | CVS | Stock Option | Common Stock (48,230) | $34.96 | April 1, 2018 | 48,230 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 14 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Feb. 3, 2023 | CVS | Common Stock | 34,672 | Direct |
| June 21, 2011 | CVS | Common Stock (restricted) [F1] | — | Direct |
| March 18, 2011 | CVS | Common Stock | 12,094 | Direct |
| March 18, 2011 | CVS | Common Stock (restricted) | — | Direct |
| March 18, 2011 | CVS | Common Stock (restricted) | — | Direct |
| March 18, 2011 | CVS | Common Stock (restricted) | — | Direct |
| March 18, 2011 | CVS | Common Stock (restricted) | — | Direct |
| March 18, 2011 | CVS | Common Stock (restricted) | — | Direct |
| March 18, 2011 | CVS | Common Stock (restricted) | — | Direct |
| March 18, 2011 | CVS | Stock Option→ Common Stock (125,250) | 125,250 | Direct |
| March 18, 2011 | CVS | Stock Option→ Common Stock (95,135) | 95,135 | Direct |
| March 18, 2011 | CVS | Stock Option→ Common Stock (77,619) | 77,619 | Direct |
| March 18, 2011 | CVS | Stock Option→ Common Stock (45,897) | 45,897 | Direct |
| March 18, 2011 | CVS | Stock Option→ Common Stock (93,903) | 93,903 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
CVS
CEO| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $1,500,000 | — | — | — | $4,695,900 | $64,644 | $453,609 | $21,214,084 |
| 2024 | $1,103,495 | — | — | — | $0 | $0 | $205,410 | $17,808,792 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.